

*What do experts say about
Biosimilars in Ophthalmology?*

Learn more at

EyeSeeYou.care



Eye See You



International
Federation on
Ageing



"It's our preference as patients to be able to make treatment decisions in an informed and educated way with our health care providers."

– Dr. Dawn Richards
Vice President, Canadian Arthritis Patient Alliance
at the EyeSeeYou Vision Health Panel
Biosimilars in Ophthalmology: Is there a big change on the horizon?



"For Fighting Blindness Canada, it's critical that decisions around biosimilars are not just driven by financial concerns and that patients have access to safe and effective treatment options."

– Mr. Doug Earle
President & Chief Executive Officer
Fighting Blindness Canada
at the EyeSeeYou Vision Health Panel
Biosimilars in Ophthalmology: Is there a big change on the horizon?



Eye See You



International
Federation on
Ageing

"Educational resources addressing concerns about biosimilars are provided by a variety of sources. Accessing this information is sometimes a challenge for individuals with vision loss who are unable to read leaflets for example."

– Ms. Louise Gillis
President, Canadian Council of the Blind
at the EyeSeeYou Vision Health Panel
Biosimilars in Ophthalmology: Is there a big change on the horizon?



Eye See You



International
Federation on
Ageing

"It's very important for older Canadians to know what questions they should be asking their ophthalmologist about treatment options."

– Mr. Jim Tokos
National Vice President,
Canadian Council of the Blind

at the EyeSeeYou Town Hall | Biosimilars in Ophthalmology: What do patients and their families need to know?



"One question I had during the consultation about switching from an originator biologic to a biosimilar was: Would I be able to switch back, and would the originator biologic still be effective?"

– Mr. Brad Hickling

at the EyeSeeYou Town Hall | Biosimilars in Ophthalmology: What do patients and their families need to know?



"Much more information, awareness and education are needed for us to get ahead of the curve and engage in policy discussions about biosimilars in ophthalmology."

– Ms. Laura Tamblyn-Watts
President & Chief Executive Officer, CanAge

at the EyeSeeYou Town Hall | Biosimilars in Ophthalmology: What do patients and their families need to know?



*The time to raise
awareness about
biosimilars in
ophthalmology is now.*

Learn more at

EyeSeeYou.care



Eye See You



International
Federation on
Ageing

